BACKGROUND & AIMS: We aimed to identify the incidence and predictors of de novo gastroesophageal variceal formation and progression in a large cohort of patients with chronic hepatitis C and advanced fibrosis. METHODS: All participants in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial were offered an endoscopy before treatment and again after 4 years. Patients with varices at baseline also had an endoscopy at 2 years. Baseline laboratory and clinical parameters were analyzed as predictors of de novo variceal formation and variceal progression. RESULTS:De novo varices developed in 157 of the 598 (26.2%) patients. Most of the new varices were small (76.4%) and only 1% of patients developed variceal hemorrhage. The likelihood of developing varices was associated with subject race (Hispanic > Caucasian > African American; P = .0005), lower baseline levels of albumin (P = .051), and higher levels of hyaluronic acid (P < .001) with an area under the receiver operating characteristic curve = .70. Among 210 patients with existing gastroesophageal varices, 74 (35.2%) hadvariceal progression or bleeding during follow-up. Patients with higher baseline ratios of serum aspartate/alanine aminotransferase (P = .028) and lower platelet counts (P = .0002) were at greatest risk of variceal progression (area under the receiver operating characteristic = .72). Prolonged, low-dose peginterferon-alpha2a therapy and beta-blockers did not influence the risk of developing new or enlarging varices. CONCLUSION: Development of varices in patients with chronic hepatitis C is associated with patient race/ethnicity and laboratory markers of disease severity. Prolonged low-dose peginterferon-alpha2a therapy and beta-blockers do not reduce the risk of variceal development or progression. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
RCT Entities:
BACKGROUND & AIMS: We aimed to identify the incidence and predictors of de novo gastroesophageal variceal formation and progression in a large cohort of patients with chronic hepatitis C and advanced fibrosis. METHODS: All participants in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial were offered an endoscopy before treatment and again after 4 years. Patients with varices at baseline also had an endoscopy at 2 years. Baseline laboratory and clinical parameters were analyzed as predictors of de novo variceal formation and variceal progression. RESULTS: De novo varices developed in 157 of the 598 (26.2%) patients. Most of the new varices were small (76.4%) and only 1% of patients developed variceal hemorrhage. The likelihood of developing varices was associated with subject race (Hispanic > Caucasian > African American; P = .0005), lower baseline levels of albumin (P = .051), and higher levels of hyaluronic acid (P < .001) with an area under the receiver operating characteristic curve = .70. Among 210 patients with existing gastroesophageal varices, 74 (35.2%) had variceal progression or bleeding during follow-up. Patients with higher baseline ratios of serum aspartate/alanine aminotransferase (P = .028) and lower platelet counts (P = .0002) were at greatest risk of variceal progression (area under the receiver operating characteristic = .72). Prolonged, low-dose peginterferon-alpha2a therapy and beta-blockers did not influence the risk of developing new or enlarging varices. CONCLUSION: Development of varices in patients with chronic hepatitis C is associated with patient race/ethnicity and laboratory markers of disease severity. Prolonged low-dose peginterferon-alpha2a therapy and beta-blockers do not reduce the risk of variceal development or progression. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: L Alric; M Duffaut; J Selves; K Sandre; M Mularczyck; J Izopet; H Desmorat; C Bureau; N Chaouche; B Dalbergue; J P Vinel Journal: J Hepatol Date: 2001-08 Impact factor: 25.083
Authors: M L Shiffman; C M Hofmann; M J Contos; V A Luketic; A J Sanyal; R K Sterling; A Ferreira-Gonzalez; A S Mills; C Garret Journal: Gastroenterology Date: 1999-11 Impact factor: 22.682
Authors: Maribel Rodriguez-Torres; Lennox J Jeffers; Muhammad Y Sheikh; Lorenzo Rossaro; Victor Ankoma-Sey; Fayez M Hamzeh; Paul Martin Journal: N Engl J Med Date: 2009-01-15 Impact factor: 91.245
Authors: Adrian M Di Bisceglie; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; James E Everhart; Elizabeth C Wright; William M Lee; Anna S Lok; Herbert L Bonkovsky; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Kristin K Snow; Jules L Dienstag Journal: N Engl J Med Date: 2008-12-04 Impact factor: 91.245
Authors: Amir A Qamar; Norman D Grace; Roberto J Groszmann; Guadalupe Garcia-Tsao; Jaime Bosch; Andrew K Burroughs; Rie Maurer; Ramon Planas; Angels Escorsell; Juan Carlos Garcia-Pagan; David Patch; Daniel S Matloff; Robert Makuch Journal: Hepatology Date: 2008-01 Impact factor: 17.425
Authors: Robert J Fontana; Zachary D Goodman; Jules L Dienstag; Herbert L Bonkovsky; Deepa Naishadham; Richard K Sterling; Grace L Su; Mita Ghosh; Elizabeth C Wright Journal: Hepatology Date: 2008-03 Impact factor: 17.425
Authors: Robert J Fontana; Arun J Sanyal; Marc G Ghany; Herbert L Bonkovsky; Timothy R Morgan; Heather J Litman; Andrea E Reid; William M Lee; Deepa Naishadham Journal: Am J Gastroenterol Date: 2010-12-07 Impact factor: 10.864
Authors: Michael J Lipp; Arkady Broder; David Hudesman; Pauline Suwandhi; Steven A Okon; Mitchell Horowitz; David J Clain; Patricia Friedmann; Albert D Min Journal: Dig Dis Sci Date: 2011-03-06 Impact factor: 3.199
Authors: Arun J Sanyal; Elizabeth M Brunt; David E Kleiner; Kris V Kowdley; Naga Chalasani; Joel E Lavine; Vlad Ratziu; Arthur McCullough Journal: Hepatology Date: 2011-07 Impact factor: 17.425
Authors: Young Seok Kim; Eun Sun Jung; Wonhee Hur; Si Hyun Bae; Jong Young Choi; Myeong Jun Song; Chang Wook Kim; Se Hyun Jo; Chang Don Lee; Young Sok Lee; Sang Wook Choi; Jin Mo Yang; Jeong Won Jang; Sang Gyune Kim; Seung Won Jung; Hee Kyung Kim; Hee Bok Chae; Seung Kew Yoon Journal: Clin Mol Hepatol Date: 2013-06-27
Authors: Kristin K Snow; Margaret C Bell; Anne M Stoddard; Teresa M Curto; Elizabeth C Wright; Jules L Dienstag Journal: Trials Date: 2014-05-07 Impact factor: 2.279